Position in ACET
as of Jun 30, 2026
· filed Aug 17, 2026
Position Value
$2,121,275
+$609,762 QoQ
Shares Held
245,518
+10.6% QoQ
Ownership
2.62%
of shares outstanding
% of Portfolio
1.63%
of 13F equity value
Holder Rank
#8
of 56 holders
Holding Since
Mar 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ACET Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Stonepine Capital Management, LLC holds $107,440,851 across 61 Biotechnology names. ACET ranks #16 (2.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VSTM |
Verastem, Inc.
|
3,349,627 | $12,795,575 | |
| 2 | TENX |
Tenax Therapeutics, Inc.
|
660,000 | $9,603,000 | |
| 3 | NKTR |
Nektar Therapeutics
|
120,654 | $8,422,855 | |
| 4 | ADMA |
Adma Biologics, Inc.
|
740,000 | $6,193,800 | |
| 5 | CAMP |
Camp4 Therapeutics Corp
|
1,389,622 | $6,072,648 | |
| 6 | ELOX |
Eloxx Pharmaceuticals, Inc.
|
397,160 | $5,512,580 | |
| 7 | KZIA |
Kazia Therapeutics Ltd
|
345,179 | $4,860,120 | |
| 8 | CRBP |
Corbus Pharmaceuticals Holdings, Inc.
|
425,000 | $3,986,500 |
All Filings in ACET
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,121,275 | 245,518 | Shares | Sole | 2026-08-17 | |
| 2026-03-31 | $1,511,513 | 221,955 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $1,852,492 | 220,011 | Shares | Sole | 2026-02-13 | |
| 2025-03-31 | $383,740 | 508,266 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $673,400 | 700,000 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $877,602 | 609,446 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $737,429 | 609,446 | Shares | Sole | 2024-08-21 | |
| 2024-03-31 | $332,637 | 141,548 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||